Kane’s DispersinB passes biocompatibility tests

Kane Biotech’s (TSX-V:KNE) DispersinB’s topical wound spray has passed FDA-recommended cytotoxicity, primary skin irritation and genotoxicity tests, with two remaining biocompatibility studies currently in progress. “Biocompatibility is critical to the commercial development of a topical wound care product and these results confirm that DispersinB spray is non-cytotoxic, non-irritant, non-mutagenic and non-genotoxic,” CSO Dr. Sri Madhyastha [...]

Kane gets DispersinB from biotech plants

Kane Biotech (TSX-V:KNE) has confirmed the invention of biotech plants producing DispersinB antibiofilm enzyme, representing a proof of concept for developing bacterial disease-resistant agricultural crops. The Company said DispersinB-expressing plants are resistant to plant pathogens due to their ability to inhibit and disrupt biofilms. In addition, this biotech plant can also be used as a [...]

In conversation with Gord Froehlich

After a 25-year stint with Monsanto Canada, where he rose to vice president, Gord Froehlich moved seamlessly into Kane Biotech (TSX-V: KNE) as VP of Business Development and then into the executive suite in 2006. While there is a myriad of differences between a biotech start-up and a global ag-biotech giant, Mr. Froehlich contends that [...]

Kane Biotech increases size of financing

Kane Biotech (TSX-V:KNE) raised the size of its previously announced private placement to a maximum of 4,335,500 units from 3,846,154 units for total proceeds of  up to $563,615.  Net proceeds will be used for the company’s research and development program, and for working capital, Kane said in a statement. Each unit consists of one common [...]